Alterity Therapeutics Limited PRNAF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 286.30K | 279.90K | 920.00K | 917.10K | 1.23M |
| Total Revenue | 286.30K | 279.90K | 920.00K | 917.10K | 1.23M |
| Cost of Revenue | 58.20K | 56.90K | 32.40K | 32.30K | 20.50K |
| Gross Profit | 228.10K | 223.00K | 887.60K | 884.70K | 1.21M |
| SG&A Expenses | 1.92M | 1.88M | 1.68M | 1.67M | 695.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 32.80K | 32.10K | 62.80K | 62.60K | 9.80K |
| Total Operating Expenses | 5.49M | 5.36M | 4.35M | 4.33M | 3.51M |
| Operating Income | -5.20M | -5.08M | -3.43M | -3.42M | -2.28M |
| Income Before Tax | -4.88M | -4.77M | -3.14M | -3.13M | -1.57M |
| Income Tax Expenses | 18.40K | 18.00K | 20.20K | 20.10K | 21.80K |
| Earnings from Continuing Operations | -4.89M | -4.78M | -3.16M | -3.15M | -1.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.89M | -4.78M | -3.16M | -3.15M | -1.59M |
| EBIT | -5.20M | -5.08M | -3.43M | -3.42M | -2.28M |
| EBITDA | -5.20M | -5.08M | -3.43M | -3.42M | -2.28M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 217.40M | 217.40M | 203.59M | 203.59M | 149.61M |
| Average Diluted Shares Outstanding | 217.40M | 217.40M | 203.59M | 203.59M | 149.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |